Imatinib, a tyrosine kinase inhibitor (TKI) that binds to c-ABL, BCR-ABL, and c-KIT and is clinically used to treat chronic myeloid leukemia and gastrointestinal stromal tumors [20], prevents fibrosis in a mouse model of bleomycin-induced lung fibrosis [21] and reduces αSMA expression in CAFs derived from colon metastatic lesions of patients [22]. The gene discussed is ABL1; the disease is gastrointestinal stromal tumor.